Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.
Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration accepted its supplemental Biologics License Application for Sprycel (dasatinib) in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Is it safe for women with heart disease to become pregnant? Usually, according to ten-year results from the ROPAC registry reported in a late breaking science session today at ESC Congress 2018.
Pregnant women with heart disease should give birth at no later than 40 weeks gestation. That is one of the recommendations in the 2018 European Society of Cardiology Guidelines for the management of cardiovascular diseases during pregnancy published online today in European Heart Journal, and on the ESC website.
Scientists at Stanley Manne Children's Research Institute at Ann & Robert H. Lurie Children's Hospital of Chicago took a major step toward developing a new treatment for pulmonary arterial hypertension, a severe lung disease with a five-year survival rate of 50 percent.
The new journal Cardiovascular Innovations and Applications has just published the first issue of Volume 3. This is a Special Issue on Adult Congenital Heart Disease with Guest Editor Diego Moguillansky of the University of Florida Medical School.
New and better ways to fight hypertension and low blood pressure may be in the offing, thanks to the National University of Singapore scientists' discovery of how our blood pressure is controlled.
The ATS Foundation is pleased to announce a new ATS Foundation/Insmed Research Award in Non-Tuberculous Mycobacteria Lung Disease, which will provide one year of funding support in the amount of $50,000.
Drug manufacturer Pfizer is coming up with a cheaper and generic version of their erectile dysfunction pill Viagra this week.
Shortness of breath and respiratory distress often increase the suffering of advanced-stage lung cancer patients. These symptoms can be triggered by pulmonary hypertension, as scientists at the Max Planck Institute for Heart and Lung Research in Bad Nauheim and the German Center for Lung Research found after examining more than 500 patients.
Extracorporeal shock-wave therapy at low energy levels showed promise as a new treatment for digital ulcers in patients with systemic sclerosis, or scleroderma, according to new research findings presented this week at the 2017 ACR/ARHP Annual Meeting in San Diego.
A team of Cleveland Clinic researchers found that a common heart disease medication, beta blockers, may help treat pulmonary arterial hypertension (PAH), a debilitating lung disease.
New treatments have extended the lives of many lung cancer patients. However, even better than treating lung cancer would be preventing it from developing in the first place.
The results of two studies presented today at the Annual European Congress of Rheumatology (EULAR) 2017 press conference highlight the use of two new tools, which can potentially play a pivotal role in the early diagnosis of Systemic Sclerosis.
The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published today in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
Researchers from the Cedars-Sinai Heart Institute and the Cedars-Sinai Department of Medicine are expanding their ongoing evaluation of a novel cell-based therapeutic candidate into the area of pulmonary arterial hypertension (PAH).
Selexipag is approved for long-term treatment of pulmonary arterial hypertension (PAH) in adults with moderate to severe symptoms.
Prescription medication costs are expected to rise at least 11 percent, and possibly up to 13 percent, in 2016, according to a new report on national trends and projections in prescription drug expenditures.
Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year.
Hepatoma-derived growth factor predicts disease severity and survival in patients with pulmonary arterial hypertension, showing some possible clinical advantages over N-terminal pro-brain natriuretic peptide, researchers report.
Johns Hopkins Medicine researchers report that rising blood levels of a protein called hematoma derived growth factor (HDGF) are linked to the increasing severity of pulmonary arterial hypertension, a form of damaging high blood pressure in the lungs.